Role of GM Companies
The real profiteers of GMO’s are neither the farmers nor the poor and hungry, but the large biotechnology companies who profit several times from the farmers’ dependency on their products.
GMO: Profitable Business
GM companies profit several times when selling modified seeds:
They annually sell expensive genetically modified seeds.
They increase the demand for their corresponding herbicides
The weed resistance further increases the demand for more pesticides (see ecological consequences)
Monsanto for example increased the retail price for their major herbicide (Round Up) by 134% within two years!
A lot of research is done on the effects of GMO. However, it is important to take into account the commercial interest of the companies that finance most of the research and the potential bias of scientists.
- “The work in five studies (Noteborn et al., 1995; Hammond et al., 1996, Brake and Vlachos, 1998; Hashimoto et al., 1999, Teshima et al., 2000) was regarded as having been performed more or less in collaboration with private companies. Effects related to GM-materials were not reported in any of these studies. On the other hand, adverse effects were reported (but not explained) in independent studies by Pusztai (1998, 2002), Fares and El-Sayed (1998), Ewen and Pusztai (1999) and Pusztai et al., (1999). It is remarkable that these effects have all been observed after feeding for only 10–14 days.” (Pryme and Lembcke,2003)
Furthermore, companies often restrict the access to their developments. Thus, independent research is not possible. This was highlighted in a statement by 26 leading scientists at public research institutions in the US.
- "Technology/stewardship agreements required for the purchase of genetically modified seed explicitly prohibit research. These agreements inhibit public scientists from pursuing their mandated role on behalf of the public good unless the research is approved by industry. As a result of restricted access, no truly independent research can be legally conducted on many critical questions regarding the technology, its performance, its management implications, IRM, and its interactions with insect biology. Consequently, data flowing to an EPA Scientific Advisory Panel from the public sector is unduly limited." (Source)